Vertex Pharmaceuticals Incorporated (VRTX) 2024 10-K Earnings Analysis
Vertex Pharmaceuticals Incorporated2024 Earnings Analysis
77/100
Vertex's FY2024 10-K shows $11.0B revenue, $-0.54B reported net loss (driven by approximately $4.4B of acquired-IPRD charges from the Alpine Immune Sciences acquisition closed April 2024 per the closing press release), 86.1% gross margin, and -$0.8B operating cash flow. Stripping the IPRD charge, the underlying franchise economics remain strong — driven by the cystic-fibrosis triple-combination Trikafta/Kaftrio. The 2024 launch of Casgevy (the first FDA-approved CRISPR therapy for sickle cell and beta thalassemia per the December 2023 FDA-approval press release, partnered with CRISPR Therapeutics) opens a new modality. Reshma Kewalramani has served as CEO since April 2020.
Filing analysis
Vertex Pharmaceuticals Incorporated 2024 10-K Analysis
This page reads Vertex Pharmaceuticals Incorporated's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 77/100, or grade C.
VRTX Earnings Quality
The earnings-quality module scores 74/100, with Gross Margin: 86.1%, Reported Net Loss: -$0.54B. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
VRTX Economic Moat Analysis
The moat-strength module scores 86/100, with CFTR-Modulator Franchise: Vanzacaftor pipeline, Casgevy CRISPR Launch: First CRISPR therapy. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
VRTX Free Cash Flow vs Net Income
Operating Cash Flow: -$0.5B is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
VRTX Key Risks from the Annual Report
The risk module scores 68/100, with CF Franchise Concentration: Single-disease, Casgevy Commercial Ramp: Complex therapy. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is VRTX a High Quality Earnings Stock?
Based on this 2024 filing, VRTX needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 74/100. This is a research screen, not investment advice.
Read the report first
Understand Vertex Pharmaceuticals Incorporated first, then decide if it belongs on your watchlist
The VRTX score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep VRTX with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the VRTX report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 86.1% reflects branded-biotech CFTR-modulator economics. The Trikafta/Kaftrio franchise carries the high-margin profile typical of orphan-drug-protected biopharma per the product-revenue disclosures.
Per the FY2024 10-K income statement, the reported net loss of $0.54B is driven by approximately $4.4B of acquired-IPRD (in-process R&D) charges from the April 2024 Alpine Immune Sciences acquisition disclosed in the acquisitions footnote — a non-cash purchase-accounting item.
Per the FY2024 cash flow statement, OCF of -$0.5B reflects the cash component of the Alpine acquisition (cash consideration paid through operating-activities cash flow per the acquisition-accounting treatment) and other working-capital effects. Underlying core-operating cash generation is better understood by normalizing for the acquisition-cash impact.
Per the FY2024 product-revenue disclosures, Trikafta (US brand) / Kaftrio (EU brand) is the principal Vertex revenue source — the triple-combination CFTR modulator approved across multiple cystic-fibrosis-genotype groups per the FDA and EMA-approved labels.
Earnings quality scores 74/100. Per the FY2024 10-K, Vertex's $11.0B revenue produces an 86.1% gross margin but the reported net loss of $0.54B is distorted by approximately $4.4B of acquired-IPRD charges from the April 2024 Alpine Immune Sciences acquisition per the closing press release. Operating cash flow of -$0.5B reflects the cash component of the same acquisition. Underlying franchise economics remain strong — driven by the Trikafta/Kaftrio CFTR-modulator franchise per the product-revenue disclosures.
Moat Strength
Per the FY2024 10-K product-portfolio disclosures, Vertex's CFTR-modulator franchise covers Trikafta/Kaftrio plus the next-generation vanzacaftor-tezacaftor-deutivacaftor triple combination (FDA-approved December 2024 as Alyftrek per the regulatory press release) extending the CFTR-modulator-franchise lifecycle into the late-2020s and 2030s.
Per the December 2023 FDA-approval press release for Casgevy (exa-cel) — partnered with CRISPR Therapeutics per the disclosed collaboration — Casgevy is the first FDA-approved CRISPR-based gene-editing therapy. Indications cover sickle cell disease and transfusion-dependent beta thalassemia per the approved label.
Per the FY2024 10-K pipeline disclosures, Vertex has expanded into non-CF indications — Suzetrigine (formerly VX-548 for acute pain, FDA-approved January 2025 as Journavx per the regulatory press release), the inaxaplin/VX-147 IgA-nephropathy program, and the Alpine-acquired povetacicept lupus-nephritis asset (the rationale for the April 2024 acquisition per the announcement press release).
Goodwill of $1.1B on $23B assets equals 4.8% per the FY2024 balance sheet — modest reflecting principally organic R&D growth. The Alpine acquisition added some goodwill but most of the Alpine purchase-price was allocated to the IPRD line per the acquisition footnote.
Moat strength scores 86/100. Per the FY2024 10-K, Vertex's competitive position rests on (1) the CFTR-modulator franchise (Trikafta/Kaftrio + the December 2024 FDA-approved Alyftrek per the regulatory press release) extending the cystic-fibrosis lifecycle, (2) Casgevy as the first FDA-approved CRISPR therapy per the December 2023 approval announcement, partnered with CRISPR Therapeutics, (3) the non-CF pipeline build (Journavx/Suzetrigine pain — January 2025 FDA approval per the regulatory disclosure, IgA-nephropathy inaxaplin, Alpine-acquired povetacicept lupus nephritis), and (4) the modest 4.8% goodwill reflecting organic-growth posture.
Capital Allocation
Per the FY2024 cash flow statement and prior-year FCF disclosures, Vertex's underlying core-operating cash generation has been strong before the Alpine-acquisition-cash impact. The disclosed prior-period FCF figures provide the baseline for normalized capacity.
Per Vertex's April 2024 Alpine Immune Sciences closing press release, Vertex completed the approximately $4.9B all-cash acquisition. The disclosed strategic rationale is the povetacicept (B-cell-targeted) asset for IgA-nephropathy and lupus-nephritis-related autoimmune indications.
Per the FY2024 capital-return disclosures, Vertex does not pay a regular dividend; share repurchases are the disclosed shareholder-return mechanism. Capital allocation prioritizes pipeline R&D and selective M&A per investor-day materials.
Per the FY2024 balance sheet, cash and short-term investments of $4.6B (post-Alpine) provide strategic flexibility. No material debt outstanding per the debt-schedule footnote.
Capital allocation scores 78/100. Per the FY2024 10-K, Vertex's principal FY2024 capital-deployment event was the April 2024 Alpine Immune Sciences acquisition (approximately $4.9B all-cash per the closing press release). Underlying cash generation excluding the acquisition outflow remains strong per prior-year disclosures. No regular dividend; capital is allocated to pipeline R&D, selective M&A, and share repurchase per the disclosed framework.
Key Risks
Per the FY2024 product-revenue disclosures, the CFTR-modulator franchise (Trikafta/Kaftrio plus Alyftrek launch) represents the dominant share of Vertex revenue. Single-indication concentration is a structural risk — though the disclosed pipeline (Journavx, povetacicept, inaxaplin, Casgevy) is the diversification trajectory.
Per the FY2024 Casgevy-launch disclosures and trade-press coverage of cell-and-gene-therapy commercial dynamics, gene-edited therapies face complex commercial-rollout dynamics — authorized treatment center qualification, payer-coverage decisions, and patient-eligibility identification. Ramp cadence is tracked in quarterly investor communications.
Per the FY2024 Risk Factors and ClinicalTrials.gov-registered programs, Vertex's pipeline depends on clinical-trial readouts across non-CF indications — particularly the post-Alpine povetacicept programs, the IgA-nephropathy inaxaplin program, and additional candidates. Trial-readout outcomes shape the multi-year revenue-replacement trajectory.
Per HHS CMS public communications under the Inflation Reduction Act, Medicare drug-price-negotiation rounds will progress over multi-year periods. Trikafta is a multi-billion-dollar Medicare-relevant orphan drug; selection in future negotiation rounds is a long-horizon variable disclosed in the Risk Factors.
Risk profile scores 68/100 (higher = safer). Per the FY2024 10-K, the principal watch-items are (1) CFTR-modulator-franchise revenue concentration mitigated by the disclosed non-CF pipeline build, (2) Casgevy gene-therapy commercial-ramp dynamics typical of cell-and-gene therapy launches per industry trade-press coverage, (3) pipeline-trial-readout risk for povetacicept, inaxaplin, and other programs per ClinicalTrials.gov, and (4) long-horizon Medicare IRA drug-price-negotiation exposure on Trikafta per CMS public communications.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.